Stimcell Energetics Inc. reported a net loss of $895,375 for the fiscal year ending May 31, 2026, a 58.1% increase from the previous year's loss of $566,293. The company did not generate any revenue during this period, continuing a trend from the prior year. Operating expenses rose by 58.2% to $826,027, driven primarily by a significant increase in general and administrative expenses, which surged by 79.2% to $382,560, and research and development costs, which increased by 226.8% to $209,176. The company’s accumulated deficit now stands at $11,756,931.
In terms of strategic developments, Stimcell completed a 1-for-15 reverse stock split on November 1, 2024, and changed its name from Cell MedX Corp. to Stimcell Energetics Inc. The company has engaged ADM Tronics Unlimited, Inc. to redesign its eBalance® Home device into a more compact and affordable unit, expected to be ready for market in early 2026. However, due to financial constraints, the company suspended further research and development of its eBalance® technology during the fiscal year.
Operationally, the company reported a working capital deficit of $1,811,320 as of May 31, 2026, an increase of 45.3% from the previous year. Current liabilities rose by 49.3% to $1,892,774, while current assets increased significantly to $81,454, up 283.8% from $21,222. The company has relied on related party loans to fund its operations, borrowing $300,582 during the year from related parties at a 10% interest rate.
Looking ahead, Stimcell's management has indicated that the continuation of operations is contingent upon securing additional financing. The company is exploring options for raising capital to support its ongoing operations and the development of its eBalance® technology. However, there is no assurance that these efforts will be successful, raising substantial doubt about the company's ability to continue as a going concern.
About Stimcell Energetics Inc.
Stimcell Energetics Inc. develops microcurrent-based devices aimed at enhancing cellular function, wellness, and managing health conditions such as diabetes, pain, and neuropathy. Its proprietary eBalance® technology supports health through electrical therapy systems for clinical and home use. The company focuses on research, regulatory approval, and commercialization of its medical devices, targeting chronic disease management and wellness markets worldwide.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.